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A B S T R A C T
Purpose: Intracerebral delivery of anti-epileptic compounds represents a novel strategy for the
treatment of refractory epilepsy. Adenosine is a possible candidate for local delivery based on its proven
anti-epileptic effects. Neural stem cells constitute an ideal cell source for intracerebral transplantation
and long-term drug delivery. In order to develop a cell-based system for the long-term delivery of
adenosine, we isolated neural progenitor cells from adenosine kinase deﬁcient mice (Adk/) and
compared their differentiation potential and adenosine release properties with corresponding wild-type
cells.
Methods: Fetal neural progenitor cells were isolated from the brains of Adk/ and C57BL/6 mice fetuses
and expanded in vitro. Before and after neural differentiation, supernatants were collected and assayed
for adenosine release using liquid chromatography–tandem mass spectrometry (LC–MS/MS).
Results: Adk/ cells secreted signiﬁcantlymore adenosine compared towild-type cells at any time point
of differentiation. Undifferentiated Adk/ cells secreted 137  5 ng adenosine per 105 cells during 24 h in
culture, compared to 11  1 ng released from corresponding wild-type cells. Adenosine release was
maintained after differentiation as differentiated Adk/ cells continued to release signiﬁcantly more
adenosine per 24 h (47  1 ng per 105 cells) compared to wild-type cells (3  0.2 ng per 105 cells).
Conclusions: Fetal neural progenitor cells isolated from Adk/mice – but not those from C57BL/6mice –
release amounts of adenosine considered to be of therapeutic relevance.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a chronic neurological disorder with a prevalence
between 0.5 and 1%.1,2 Despite the availability of several anti-
epileptic drugs, about 30% of patientswith epilepsy still suffer from
uncontrolled seizures or medication-related side effects.3 Intrace-
rebral delivery of anti-epileptic compounds represents a novel
strategy for the treatment of refractory epilepsy.4,5 Adenosine is a
possible candidate for local delivery because of its proven anti-
epileptic effects. Systemic application of adenosine is not possible
because of severe side effects such as decreased heart rate, blood
pressure and body temperature.6 Adenosine is a ubiquitous
neuromodulator of the brain and acts via binding to G-protein
coupled adenosine receptors. The inhibitory effect of adenosine is
mainly due to binding to the high-afﬁnity A1 receptor that is* Corresponding author. Tel.: +32 9 332 6946; fax: +32 9 332 4971.
E-mail address: Annelies.VanDycke@UGent.be (A. Van Dycke).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.05.010expressed in cerebral cortex, hippocampus, thalamus, cerebellum,
brain stem and spinal cord.7,8 Several in vivo studies have already
proven the feasibility and anti-seizure effects of local delivery of
adenosine in different animal models.9–13 In those studies, a
synthetic adenosine-releasing polymer or encapsulated adeno-
sine-releasing cells from different sources were implanted into the
lateral ventricle of kindled rats. However, the anti-seizure effect of
adenosine decreased during the secondweek of treatment because
of expiration of adenosine release from the polymer or limited
long-term viability of the encapsulated cells. Further attempts to
extend the adenosine release resulted in the successful develop-
ment of a silk protein-based release system for adenosine.
Implantation of this system in the infrahippocampal ﬁssure of
rats resulted in seizure protection and retardation of kindling
acquisition.14,15 However, these therapeutic effects lasted for a
maximum of 10 days, corresponding to the duration of adenosine
release from this system. Since epilepsy is a chronic disorder and
lifelong treatment is required, development of an implantable
adenosine source that is able to produce a sufﬁcient and stablevier Ltd. All rights reserved.
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promising technique may be local delivery via implantation of
stem cells.16–18
In brain, adenosine can be metabolized and removed by three
enzymes that control levels of ambient intracellular adenosine:
adenosine kinase (ADK), adenosine deaminase (ADA) and S-
adenosyl-homocysteine hydrolase (SAHH). Based on its low KM
for adenosine, the key enzyme for the control of adenosine levels is
ADK,19,20 which, in adult brain, is almost exclusively expressed in
astrocytes.21OverexpressionofADK isapathologicalhallmarkof the
epileptic brain and associated with a deﬁciency of the endogenous
anticonvulsant adenosine and the expression of spontaneous
seizure activity.22–25 Therefore, inhibition of ADK constitutes a
neurochemical rationale to increase adenosine levels and to provide
seizure control. To this end adenosine-releasing embryonic stem
cells havebeenengineeredbased ona bi-allelic geneticdisruption of
the Adk-gene,26 and successfully been used to suppress kindling
acquisition in rats27 and the development of epilepsy in mice.24 In
these experiments it was necessary to differentiate the embryonic
stem cells before implantation to avoid teratoma formation and
genetic alterations by undifferentiated embryonic stem cells.28,29
Several strategies are available to improve functional and safety
concerns of embryonic stemcells.Differentiationof embryonic stem
cells can be controlled by speciﬁc selection and culture procedures
or genetic modiﬁcation. Genetic aberrations must be excluded by
early passage karyotyping and tumor formation can be excluded by
depletion of tumorigenic cells or enrichment of non-tumorigenic
cells.30 Nevertheless it remains to be proven whether these
strategies are sufﬁcient to guarantee long-term survival and
therapeutic action. Isolation of fetal or adult stem cells could avoid
these ethical and practical problems coupled to embryonic stem
cells and improve the safety ofneural transplantationapproaches. In
addition, the transplantation of neural stem cells may have
additional beneﬁts since they have the potential ability to integrate
in the neural network.31 Combination with local delivery of an anti-
epileptic substance like adenosine may lead to a promising and
effective therapy. As a potential cell source, an adenosine kinase
knockout mouse (Adk/) has been developed.32 Since Adk/mice
die within 14 days due to hepatic steatosis, the isolation of adult
neural Adk/ stem cells is not a possibility.32 In this paper we
describe the isolation and characterization of Adk/ fetal neural
progenitor cells as a source for therapeutic adenosine delivery.
Neural differentiation in vitro and adenosine secretion is compared
with wild-type cells derived from C57BL/6 mice.
2. Materials and methods
2.1. Animals
Mice [Adk+/ – breeders in the C57BL-6 background – (Robert
Stone Dow Neurobiology Laboratories, Legacy Research, USA) and
matching wild-type C57BL/6 mice (Harlan, The Netherlands)] were
housed according to the guidelines approved by the EuropeanEthics
Committee (decree 86/609/EEC). The study protocol was approved
by the Animal Experimental Ethics Committee of Ghent University
Hospital (ECP07/25). The animalswere kept under environmentally
controlled conditions (12 h normal light/dark cycles, 21–22 8C and
50% relative humidity) with food and water ad libitum.
2.2. Isolation of neural stem cells
Fetal neural stem cells were isolated from Adk/ andwild-type
C57BL/6 mice fetuses at embryonic day 14 (E14). Four pregnant
mice from Adk+/  Adk+/ matings (all mutants were maintained
in the C57BL/6 background) and two pregnant C57BL/6 mice were
sacriﬁced by cervical dislocation; the uteri were removed andtransferred to a dish with ice-cold phosphate buffered saline (PBS).
The uterine horns were opened and the fetuses removed. Their
brains were removed and placed in separate dishes with ice-cold
PBS. The cortex was isolated via microdissection and put into
culture medium (see below). The tissue was dissociated by
trituration, followed by centrifugation at 80 g for 10 min. The
pellet was resuspended in fresh medium and the cells were
counted. Their viability was checked with the trypan blue
exclusion method and cells were cultured in T25 ﬂasks at a
density of 10,000/cm2.
The neural stem cell growthmedium consisted of NS-Amedium
(StemCell Technologies SARL, Grenoble, France) with an additional
2 mM L-glutamine (Cambrex, Verviers, Belgium), 3 mM D-glucose
(Sigma, Bornem, Belgium), 2% B27 (Invitrogen, Merelbeke, Bel-
gium), 1% N2 supplement (Invitrogen), 100 U/ml penicillin
(Cambrex), 100 U/ml streptomycin (Cambrex), 20 ng/ml of human
recombinant epidermal growth factor (EGF, Sigma) and 20 ng/ml
of recombinant human basic ﬁbroblast growth factor (bFGF, R&D,
Abingdon, UK). Cells were grown at 37 8C in 5% CO2 and 95% air
with saturated humidity. They were passaged once cell clusters,
with a diameter of about 100 mm, were formed, approximately 2
weeks after initial isolation. Subsequent passages were done every
4–5 days.When sufﬁciently large cell numberswere obtained, cells
were further cultured in T75 ﬂasks at a density of 10,000 cells/cm2.
2.3. PCR of adenosine-releasing cells
Since the fetuses were derived from two heterozygote
Adk+/  Adk+/ matings, cell colonies of three different genotypes
(Adk+/+, Adk+/ and Adk/) were isolated and genotyped by PCR.
DNA from expanded cell colonies was extracted using the GenElute
Mammalian Genomic DNA Puriﬁcation Kit (Sigma) and subjected to
PCR with allele-speciﬁc primer sets. PCR reactions were performed
under standard conditions using three primers simultaneously:
o107, 50-CTC ACT TAA GCT GTA TGG AGGTGACCG-30- (sense primer
speciﬁc forwild-typeAdk), o108, 50-AGTCACAGATGCATCTGCAGA
GGT GAG-30- (antisense primer speciﬁc for wild-type Adk), and
o109, 50-ACT GGG TGC TCA GGT AGT GGT TGT CG-30- (antisense
primer speciﬁc for targeting construct).
2.4. Western Blot
Western Blot analysis for ADK expressionwas performed on cell
lysates of undifferentiated and differentiated Adk/ cells. Corre-
sponding wild-type cells served as control. GAPDH expression was
used to control for protein concentration.
Following harvesting and washing the cells with PBS, total cell
lysates were made by adding Laemmli buffer followed by
sonication. Protein concentration was measured and protein
extracts were applied to a 4–12% Bis–Tris gel (Invitrogen) for
electrophoresis by using MES/SDS running buffer (Invitrogen).
Then proteins were transferred to Protran Nitrocellulose Hybrid-
ization Transfer membrane (0.2mm pore size; PerkinElmer,
Belgium) with transfer buffer (Invitrogen). After the blotting
process, the membranes were blocked for 1 h in Tris Buffered
Saline (TBS) containing 0.075% Tween 20 (Invitrogen) and 5%
nonfat milk, followed by addition of the primary antibodies: rb
anti-ADK 1:6000 (custom made at RS Dow Neurobiology
Laboratories, Legacy Research, Portland, USA) or ms anti-GAPDH
1:1000 (Santa Cruz Biotechnology, sc-47724). Primary antibodies
were incubated for 1 h. After rinsing, secondary antibodies anti-rb/
ms IgG Horseradish Peroxidase 1:3000 were added during 90 min
at room temperature (GE Healthcare, Buckinghamshire, UK,
NA934/NA931). After thorough rinsing, signals were visualized
using a commercial enhanced bioluminescence detection method
(ECL) kit (Invitrogen).
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To evaluate the expression of neural stem cell markers (nestin,
GFAP and Sox-2), Adk/ cells and corresponding wild-type cells
were plated at a density of 20,000 cells/cm2 on laminine coated
(3 mg/cm2, Roche Diagnostics, Vilvoorde, Belgium) chamber slides
(VWR International, Leuven, Belgium). The cells were plated in
neural stem cell growth medium without addition of the growth
factor EGF for 24 h. Then they were ﬁxed with 4% paraformalde-
hyde (PFA) for 15 min and subjected to immunocytochemistry (see
below).
For neural differentiation, Adk/ cells and corresponding wild-
type cells were plated for 24 h in neural stem cell growth medium
without the addition of EGF at a density of 50,000 cells/cm2 on
laminine coated (3mg/cm2) chamber slides. Then the medium was
changed to neural stem cell growthmediumwithout added growth
factors but with the addition of 3% Fetal Calf Serum (FCS, Serum
Supreme, Cambrex). On day 7 cells were ﬁxed with 4% PFA and
subjected to immunocytochemistry for the three different neural
phenotypes: neurons (tau), glial cells (GFAP) and oligodendrocytes
(RIP). The ﬁxed cells were rinsed with 50 mM NH4Cl for 10 min
(quenching), permeabilized and blocked in PBS containing 0.4% ﬁsh
skingelatine (FSG)and0.3%TritonX-100 (PBS/FSG/TX100). Thiswas
followed by incubation overnight at 4 8C with primary antibodies
(ms, mouse monoclonal; rb, rabbit polyclonal): rb anti-Sox2 1:1000
(Chemicon, Brussels, Belgium, AB5603), rb anti-nestin 1:5000
(Eurogentec, Seraing, Belgium, PRB-315C-0100), rb anti-tau
1:2000 (Dako, Heverlee, Belgium; A0024), rb anti-GFAP 1:400
(Dako, Z0334), ms anti-RIP 1:5000 (Chemicon, MAB1580). After
rinsing, the cells were incubated with the secondary antibodies
Alexa Fluor 594 goat anti-rabbit IgG 1:1000 (Invitrogen, A11072) or
Alexa Fluor 594 goat anti-mouse IgG 1:1000 (Invitrogen, A11020)
diluted in PBS/FSG/TX100 for 2 h each. Chamber slides were then
rinsed and nuclei were stained with 0.3mM 40-6-diaminido-2-
phenylindole (DAPI, Invitrogen) for 1 min. After additional rinsing,
slides were mounted with Vectashield mounting medium (Labcon-
sult, Brussels, Belgium). To assess the fraction of cells expressing a
speciﬁc marker, immunopositive cells were counted in nine
randomly selected high power ﬁelds. The relative amount of cells
positive for a speciﬁc marker was obtained by dividing the total
number of immunopositive cells by the total number of nuclei
counted. The cells were evaluated under a ﬂuorescencemicroscope.
In control slides the primary antibody was omitted and no
immunostaining was detected in these controls.
2.6. In vitro adenosine release
The amount of adenosine released from the cells was assessed
from plated cells. Adenosine release from Adk/ cells was
compared with adenosine release from corresponding wild-type
cells and this under different experimental conditions. First,
samples were collected from supernatants of non-differentiated
cells. Therefore cells were plated at densities of 10,000 cells/cm2
and 100,000 cells/cm2 in a laminine coated (3mg/cm2) 96-well
plate (200ml medium/well) in neural stem cell growth medium
without EGF. After 24 h, medium was replaced with fresh medium
without growth factors but with addition of the adenosine
deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine hy-
drochloride (EHNA, 50 mM, Sigma). The addition of EHNA was
necessary to prevent adenosine breakdown in the culturemedium.
It has been shown that addition of EHNA to cultured neurons or
astrocytes is not toxic for the cells.33 At different time points after
medium replacement (1 h, 2 h, 4 h, 8 h, 12 h and 24 h) samples of
200 ml supernatants were taken, each time from a different well.
Samples were subsequently frozen at20 8C until later analysis. At
each time point six samples were taken.Second, a similar protocol was performed to collect samples
from differentiated cells. For this condition, cells were plated at a
density of 50,000 cells/cm2 in a laminine coated (3mg/cm2) 96-
well plate (200ml medium/well) in neural stem cell growth
medium without EGF. After 24 h the medium was changed to
neural stem cell growth medium without growth factors but with
addition of 3% FCS. Seven days later medium was replaced with
fresh mediumwithout growth factors or FCS but with the addition
of EHNA (50 mM) and samples of supernatants were collected (1 h,
2 h, 4 h, 8 h, 12 h and 24 h after medium replacement; six samples
per time point) and frozen for later analysis.
At each sample collection, cells were counted with the trypan
blue exclusion method and averaged. These data were used for
normalization and quantiﬁcation of adenosine release per cell
number.
2.7. Sample analysis
Samples were analyzed using liquid chromatography–tandem
mass spectrometry (LC–MS/MS) according to an earlier described
protocol.34 Liquid chromatographic separation was performed
using an Agilent LC 1100 HPLC system (Agilent Technologies, Santa
Clara, US) equipped with a quaternary pump, a column oven and a
100 well-plate autosampler. The LC was coupled to an API 2000
Triple Quadrupole system (Applied Biosystems/MDS Sciex, Foster
City, US) equipped with an APCI interface. Chromatographic
separation was done using a reversed phase column, the XBridge
C8 column 4.6 mm  75 mm, 3.5 mm (Waters, Zellik, Belgium) and
the temperature of the column oven was set at 40 8C. The solvent
system consisted of 2 mM ammonium acetate in water (A) and
2 mM ammonium acetate in methanol (B). An isocratic elution
with 65%A and 35% B (v/v)was usedwith a ﬂow ratewas of 500 ml/
min and an injection volume of 5ml. The total run timewas 4.5 min
per analytical run. Mass spectrometer analysis was set up in
selected reaction monitoring (SRM) in positive polarity. Based on
the component dependent parameters the SRM transitions of m/z
268.2/136.1 and 302.2/170.0 were selected, respectively for
adenosine and IS.
Before analysis of the samples, 2-chloroadenosine (1000 ng/ml,
20 ml) was added as internal standard to each sample. At each
analytical run a new calibration curve was made consisting of a
dilution series of 10 concentrations of adenosine in medium with
addition of internal standard.
2.8. Data analysis and statistics
At each sample collection, six different replicates were taken
and the mean was calculated. Adenosine secretion from differen-
tiated and non-differentiated cells was normalized to secretion per
105 cells. Statistical evaluation (SPSS 15.0) was performed using
parametric tests. All data were expressed as means and standard
errors of the mean. p < 0.05 indicates a signiﬁcant difference.
3. Results
Neurosphere-forming cells were isolated as described above
from the cortex of E14 fetal mice derived from Adk+/  Adk+/
matings and from respective wild-type dams. Approximately 2
weeks after initial isolation –when their diameter ranged from100
to 150mm – neurospheres could be passaged mechanically and
further passageswere performed every 4–5 days. At passage 7, PCR
analysis with allele-speciﬁc primer sets (o107, o108 and o109)was
performed (Fig. 1A). The wild-type speciﬁc primer set (o107/o108)
gave rise to a 640 bp band, whereas the knockout speciﬁc primer
set (o107/o109) showed a 840 bp band. Based on PCR results one
cell clone homozygous for Adk/ and one from the C57BL/6
[(Fig._1)TD$FIG]
Fig. 1. PCR and Western Blot. (A) PCR: results of isolated cells from Adk+/  Adk+/ matings. Based on these results, an Adk/ clone needed for the experiment could be
detected. The genomic DNA was ampliﬁed using the three allele-speciﬁc primers o107, o108 and o109. DNA from Adk+/ cells gives a combination of the wild-type speciﬁc
640 bp band (primers o107/o108) and the knockout-speciﬁc 840 bp band (primers o107/o109), while DNA from Adk/ cells gives rise to only a 840 bp band (primers o107/
o109), demonstrating the bi-allelic genetic disruption of the Adk locus. (B) Western Blot: above the GAPDH immune reactivity for protein control is shown (38 kDa). Beneath
ADK immune reactivity is shown (44–46 kDa). A clear reactivity is found inwild-type cells, whereas no reactivity is found in non-differentiated and differentiated Adk/ cells
(CO = control wild-type; KO 1d = Adk/ after 24 h; KO 1w = Adk/ after 1 week).
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protein extracts from both cell clones were investigated with
Western Blot analysis for ADK expression (Fig. 1B). The control
cells showed expression for ADKwhereas no expression was found
in the Adk/ cell clones, conﬁrming the PCR results.
To analyze stem cell properties for both cell clones, we
performed immunohistochemical staining of the undifferentiated
isolated cells. Three neural stem cell markers (nestin, GFAP and
Sox-2) were evaluated and expression of all markers was found in
both Adk/ andwild-type cells (Fig. 2A–D). For the nuclearmarker
Sox-2, we performed a quantitative analysis by randomly selecting
nine high power ﬁelds (200) under a ﬂuorescence microscope.
The amount of immunopositive cells was counted together with
[(Fig._2)TD$FIG]
Fig. 2. Expression of neural stem cell markers. Left: Immunostaining with nestin (red) an
Immunostaining with Sox2 (red) in Adk/ cells (B) and wild-type cells (D). Scale bar =the total number of nuclei. The results revealed Sox-2 expression in
361/570 (63%) of the Adk/ cells and in 324/528 (61%) of the
corresponding wild-type cells.
Since Adk/ cells were obtained by genetically manipulation,
their differentiation potential was evaluated and compared with
wild-type cells. Therefore cells were subjected to growth in
differentiationmedium for 7 days followed by immunohistochem-
ical staining for the three different neural phenotypes: neurons
(tau), glial cells (GFAP) and oligodendrocytes (RIP). Both Adk/
cells and wild-type cells expressed tau and GFAP (Fig. 3A–D).
Quantitative analysis – as described above for the Sox-2 marker –
demonstrated expression of tau in 6% (42/694) and GFAP in 28%
(178/640) of the Adk/ cells. Similar ratios were obtained in wild-d GFAP (green) in Adk/ cells (A) and wild-type cells (C). Scale bar = 100 mm. Right:
50 mm. Nuclei are stained with DAPI (blue).
[(Fig._3)TD$FIG]
Fig. 3. Glial and neural differentiation of neural progenitor cells in vitro. Left: Immunostaining with GFAP (red) in Adk/ cells (A) and wild-type cells (C). Right:
Immunostaining with tau (red) in Adk/ cells (B) and wild-type cells (D). Nuclei are stained with DAPI (blue). Scale bar = 100 mm.
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remaining cells did not express differentiationmarkers and none of
the cells expressed the oligodendrocyte marker RIP. The isolated
fetal cells therefore have a bipotential differentiation capacity
consistent for neural progenitor cells.
To analyze the amount of adenosine release, cells were plated at
different densities and cultured in undifferentiated (10,000 and
100,000 cells/cm2) and differentiated (50,000 cells/cm2) condi-
tions. After sample collection, cells from different wells per
condition were counted and averaged. These data were used for
normalization of adenosine release per cell number. Already 1 h
after medium replacement adenosine was measured in samples
from undifferentiated (3.40  0.3 ng per 105 cells) and differentiated
(3  0.2 ng per 105 cells) Adk/ cells, whereas no adenosine
was found in samples from wild-type cells. Comparison of adenosine
release at the different time points after medium replacement
showed an accumulation of adenosine over time in (un)differentiated
Adk/ cells, whereas corresponding wild-type cells did not release
signiﬁcant amounts of adenosine (Table 1). Fig. 4 shows the adenosine
release in samples taken 24 h after medium replacement. A
signiﬁcant difference is seen between adenosine release from
Adk/ cells compared to wild-type, both in undifferentiatedTable 1
Adenosine release in non-differentiated and differentiated conditions from Adk/ cells
point per conditionwere collected and themeanwas calculated. An accumulation of aden
cells do not release signiﬁcant amount of adenosine. Adenosine release is expressed in
Time after medium replacement Non-differentiated cells
Adk/ cells
(ng adenosine/105 cells)
Wild-type
(ngadeno
1h 3.4 0.3 0
2h 9  1 0.40.2
4h 191 20.1
8h 422 40.4
12h 633 60.3
24h 1375 111(Fig. 4A) and differentiated (Fig. 4B) conditions: 137  5 ng compared
to 11  1 ng adenosine per 105 cells (non-differentiated cells,
p < 0.05) and 47  1 ng compared to 3  0.2 ng adenosine per 105
cells (differentiated cells, p < 0.05). In undifferentiated conditions,
results of Adk/ cells plated at 10,000/cm2 showed a release of
152  4 ng per 105 cells after 24 h, indicating that cell density has no
effect on the amount of adenosine secretion. These results indicate
that Adk/ cells release signiﬁcantly more adenosine compared to
wild-type cells. Furthermore the higher amount of adenosine release
is sustained in differentiated cells, meaning that they can be used as a
therapeutic source for adenosine release.
4. Discussion
In this experiment we successfully isolated a neural novel line
of Adk/ neural progenitor cells. We demonstrated their ability to
secrete amounts of adenosine – in contrast to matching wild-type
cells – which are considered to be of therapeutic relevance. Sample
analysis revealed adenosine release from 47  1 ng (differentiated
Adk/ cells) to 137  5 ng (undifferentiated Adk/ cells) per 105
cells per 24 h. These results are comparable with adenosine secretion
from Adk/ embryonic stem cell derived glial cells.26 In those formerand corresponding wild-type cells. After medium replacement six samples per time
osine release is seen over time in Adk/ cells in both conditions, whereaswild-type
ng per 105 cells.
Differentiated cells
cells
sine/105 cells)
Adk/ cells
(ngadenosine/105 cells)
Wild-type cells
(ngadenosine/105 cells)
30.2 0
50.3 0.40.3
111 10.4
191 30.5
251 30.7
471 30.2
[(Fig._4)TD$FIG]
Fig. 4. Adenosine releases from Adk/ cells (blue) and corresponding wild-type
cells (red) in 24 h. (A) Adenosine released from 100,000 non-differentiated cells:
adenosine release from Adk/ cells is signiﬁcantly higher compared to wild-type
cells. (B) Adenosine released from 100,000 differentiated cells: adenosine release
from Adk/ cells is signiﬁcantly higher compared to wild-type cells. Standard
errors are marked with black bars. Signiﬁcance is marked with an asterisk (*):
p < 0.05.
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adenosine per 105 cells per hour (i.e. around 62 ng adenosine per 105
cells per 24 h), whereas non-differentiated glial precursor cells
secreted 2.7  0.8 ng to 11.7  1.7 ng per 105 cells per hour (i.e.
around 65–280 ng adenosine per 105 cells per 24 h) depending on the
growth conditions.
The lower adenosine secretion of differentiated Adk/ cells
compared to undifferentiated Adk/ cells during the ﬁrst 24 h of
sample collectionwas a remarkable ﬁnding. Since stem cells have a
higher metabolic rate compared to differentiated cells, differences
in adenosine release during the ﬁrst 24 h might be due to
differences in their overall metabolic rate. However, adenosine
release from our differentiated cells is considered to be of
therapeutic relevance since previous studies with local adenosine
delivery in the lateral brain ventricle of rats revealed that a
continuous release of relatively low (20–50 ng per day in vitro)
adenosine concentrations lead to seizure suppression in the rat
kindling model.9,11–13 Subsequent studies with release of 1000 ng
adenosine per day using a silk-based delivery system implanted
into the infrahippocampal cleft showed sustained suppression of
evoked seizures in the kindling model.14,15 These studies demon-
strate the therapeutic potential of focal adenosine augmentation
therapies in refractory epilepsy.
Genetically engineered neural stem cells have been investigat-
ed as a tool for different neurological diseases, including refractory
epilepsy.31,35 Compared to other cell sources, such as fetal braintissue, survival capacities of neural stem or progenitor cells are
higher and more stable.18 Therefore transplantation of neural
stem/progenitor cells combined with local delivery of an anti-
epileptic substance may be a successful alternative treatment
option for refractory epilepsy.
Since Adk/ cells are genetically manipulated, it was necessary
to investigate their ability to differentiate.We subjected the Adk/
and wild-type neural progenitor cells to in vitro differentiation,
and compared their differentiation potential towards neurons and
astrocytes. We previously demonstrated the ability of neural
progenitor cells to survive in a sclerotic hippocampus in the rat
kainic acid induced status epilepticus model.36 We found that the
majority of surviving cells differentiated towards astrocytes in
vivo. Likewise, in our current experiment we found that neural
progenitor cells differentiated towards astrocytes in vitro. This
differentiation towards astrocytes may be a major advantage in
transplantation strategies for epilepsy since astrocytes are key
regulators of adenosine.22 The ultimate rationale for using this cell
source is transplantation of astrocytes derived from the Adk/
progenitor cells after predifferentiation in vitro. These cells might
be superior to integrate into the astrogliotic environment of an
epileptic hippocampus and interact with the epileptogenic process
by releasing adenosine. We recently demonstrated that local
delivery of adenosine directly into the epileptic hippocampus has
an antiseizure effect in rats with spontaneous seizures.37 Together
with the results of our former transplantation experiment36 the
new cells described here indicate that Adk/ cells offer the
possibility to stably integrate after transplantation into the brain,
and to become a long-term source for continuous local adenosine
delivery.
5. Conclusion
Compared with data from previous studies,9,11–15 we conclude
that the amount of secreted adenosine – both from non-
differentiated and differentiated Adk/ cells – is sufﬁcient to
obtain a therapeutic effect in the treatment of refractory epilepsy.
Since astrocytes play a major role in the regulation of adenosine in
the brain, astrocytes derived from Adk/ neural progenitor cells
seem a promising source for local delivery of adenosine in an
epileptic brain. Further in vivo studies in relevant animal models
with spontaneous seizures should focus on effect on seizure
frequency.
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